Suppr超能文献

小儿肝移植:智利多中心项目十年经验

Pediatric liver transplantation: ten years of experience in a multicentric program in Chile.

作者信息

Uribe M, Buckel E, Ferrario M, Godoy J, González G, Hunter B, Ceresa S, Cavallieri S, Berwart F, Herzog C, Santander M T, Calabrán L

机构信息

Programa Trasplante Hepático Clinica las Condes, Hospital Luis Calvo Mackenna, Lo Fontecilla 441, Las Condes, Santiago, Chile.

出版信息

Transplant Proc. 2005 Oct;37(8):3375-7. doi: 10.1016/j.transproceed.2005.09.096.

Abstract

Liver transplantation is the only treatment for patients with terminal acute and chronic diseases. Liver transplantation was started in Chile in 1985; our pediatric program began in 1993. The aim of this paper work was to present our experience from 1993 through 2004. One hundred and thirty two orthotopic liver transplants (OLT) were performed in children of mean age 5 years and median age 4 years (8 months to 15 years). The most frequent indications were biliary atresia, (43.1%) and acute liver failure (ALF; 20.4%), whose frequent cause was unknown but viral hepatitis A was the second one. A complete liver was transplanted in 59 patients, reduced in 39, split in one, and as an auxiliary liver in another one. Living related liver transplantation was performed in 32 cases (24.2%), of which thirty included segments II and III, and two, a right liver. A terminal arterial anastomosis was performed in 102 (77.2%) recipients and a graft interposition in 32 patients (24.2%). In 16 cases, biliary reconstruction was performed through an enterobiliary anastomosis. Immunosuppression included cyclosporine (Neoral), steroids, and azathioprine with conversion to tacrolimus (Prograf) as indicated. Rejection episodes, which were always biopsy-proven, were treated either with methylprednisolone or with antibodies. Biliary complications were the most frequent (21.4%) and the second cause was vascular complications (13%). Sixty-six patients suffered an acute rejection episode. Actuarial graft survival was 81.3% at 1 year and 72% at 5 years, while actuarial graft survival for ALF was 75.9% at 1 year and 67.8% at 5 years. Our results are comparable to those reported by most international groups.

摘要

肝移植是终末期急慢性肝病患者的唯一治疗方法。肝移植于1985年在智利开展;我们的儿科项目始于1993年。本文旨在介绍我们1993年至2004年的经验。共对平均年龄5岁、中位年龄4岁(8个月至15岁)的儿童进行了132例原位肝移植(OLT)。最常见的适应证是胆道闭锁(43.1%)和急性肝衰竭(ALF;20.4%),其常见病因不明,但甲型病毒性肝炎是第二大病因。59例患者移植了完整肝脏,39例进行了减体积肝移植,1例进行了劈离式肝移植,另1例进行了辅助性肝移植。32例(24.2%)进行了活体亲属肝移植,其中30例包括Ⅱ段和Ⅲ段,2例为右肝。102例(77.2%)受者进行了终末动脉吻合,32例(24.2%)患者进行了移植物植入。16例患者通过肠胆吻合术进行胆道重建。免疫抑制包括环孢素(新山地明)、类固醇和硫唑嘌呤,必要时转换为他克莫司(普乐可复)。排斥反应均经活检证实,采用甲泼尼龙或抗体治疗。胆道并发症最为常见(21.4%),其次是血管并发症(13%)。66例患者发生急性排斥反应。移植肝1年实际生存率为81.3%,5年为72%,而ALF患者移植肝1年实际生存率为75.9%,5年为67.8%。我们的结果与大多数国际组织报告的结果相当。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验